These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 34298770)

  • 1. Evolving Castration Resistance and Prostate Specific Membrane Antigen Expression: Implications for Patient Management.
    Kessel K; Bernemann C; Bögemann M; Rahbar K
    Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 177Lu-PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer: A Mini-Review of State-of-the-Art.
    AlSadi R; Bouhali O; Dewji S; Djekidel M
    Oncologist; 2022 Dec; 27(12):e957-e966. PubMed ID: 36288537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy.
    Baum RP; Kulkarni HR; Schuchardt C; Singh A; Wirtz M; Wiessalla S; Schottelius M; Mueller D; Klette I; Wester HJ
    J Nucl Med; 2016 Jul; 57(7):1006-13. PubMed ID: 26795286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate-specific membrane antigen theranostics in advanced prostate cancer: an evolving option.
    Mayor N; Sathianathen NJ; Buteau J; Koschel S; Antón Juanilla M; Kapoor J; Azad A; Hofman MS; Murphy DG
    BJU Int; 2020 Nov; 126(5):525-535. PubMed ID: 32559353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving
    Kessel K; Seifert R; Weckesser M; Roll W; Humberg V; Schlack K; Bögemann M; Bernemann C; Rahbar K
    Theranostics; 2020; 10(17):7645-7655. PubMed ID: 32685010
    [No Abstract]   [Full Text] [Related]  

  • 6. Radioligand Therapy With
    Yadav MP; Ballal S; Sahoo RK; Dwivedi SN; Bal C
    AJR Am J Roentgenol; 2019 Aug; 213(2):275-285. PubMed ID: 30995089
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with
    Heck MM; Tauber R; Schwaiger S; Retz M; D'Alessandria C; Maurer T; Gafita A; Wester HJ; Gschwend JE; Weber WA; Schwaiger M; Knorr K; Eiber M
    Eur Urol; 2019 Jun; 75(6):920-926. PubMed ID: 30473431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PSMA Theranostics: Current Status and Future Directions.
    Rahbar K; Afshar-Oromieh A; Jadvar H; Ahmadzadehfar H
    Mol Imaging; 2018; 17():1536012118776068. PubMed ID: 29873291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of
    Yadav MP; Ballal S; Sahoo RK; Tripathi M; Seth A; Bal C
    Theranostics; 2020; 10(20):9364-9377. PubMed ID: 32802197
    [No Abstract]   [Full Text] [Related]  

  • 10. Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer.
    Fendler WP; Reinhardt S; Ilhan H; Delker A; Böning G; Gildehaus FJ; Stief C; Bartenstein P; Gratzke C; Lehner S; Rominger A
    Oncotarget; 2017 Jan; 8(2):3581-3590. PubMed ID: 27683041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [
    Boegemann M; Schrader AJ; Rahbar K
    Urologe A; 2017 Nov; 56(11):1440-1444. PubMed ID: 28986618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-β Insensitive Genetically Targeted CD8
    Zhang Q; Helfand BT; Carneiro BA; Qin W; Yang XJ; Lee C; Zhang W; Giles FJ; Cristofanilli M; Kuzel TM
    Eur Urol; 2018 May; 73(5):648-652. PubMed ID: 29275833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer.
    Paschalis A; Sheehan B; Riisnaes R; Rodrigues DN; Gurel B; Bertan C; Ferreira A; Lambros MBK; Seed G; Yuan W; Dolling D; Welti JC; Neeb A; Sumanasuriya S; Rescigno P; Bianchini D; Tunariu N; Carreira S; Sharp A; Oyen W; de Bono JS
    Eur Urol; 2019 Oct; 76(4):469-478. PubMed ID: 31345636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Third-line treatment and
    von Eyben FE; Roviello G; Kiljunen T; Uprimny C; Virgolini I; Kairemo K; Joensuu T
    Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):496-508. PubMed ID: 29247284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for
    Thang SP; Violet J; Sandhu S; Iravani A; Akhurst T; Kong G; Ravi Kumar A; Murphy DG; Williams SG; Hicks RJ; Hofman MS
    Eur Urol Oncol; 2019 Nov; 2(6):670-676. PubMed ID: 31412006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer].
    Fendler WP; Kratochwil C; Ahmadzadehfar H; Rahbar K; Baum RP; Schmidt M; Pfestroff A; Lützen U; Prasad V; Heinzel A; Heuschkel M; Ruf J; Bartenstein P; Krause BJ
    Nuklearmedizin; 2016 Jun; 55(3):123-8. PubMed ID: 27350005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of [
    Rosar F; Krause J; Bartholomä M; Maus S; Stemler T; Hierlmeier I; Linxweiler J; Ezziddin S; Khreish F
    Pharmaceutics; 2021 May; 13(5):. PubMed ID: 34069003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Retrospective Analysis of the Safety and Activity of Lutetium-177-Prostate-Specific Membrane Antigen Radionuclide Treatment in Older Patients with Metastatic Castration-Resistant Prostate Cancer.
    Leibowitz R; Davidson T; Gadot M; Aharon M; Malki A; Levartovsky M; Oedegaard C; Saad A; Sandler I; Ben-Haim S; Domachevsky L; Berger R
    Oncologist; 2020 Sep; 25(9):787-792. PubMed ID: 32430954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Status of PSMA-targeted radioligand therapy in prostate cancer: current data and future trials.
    Jang A; Kendi AT; Sartor O
    Ther Adv Med Oncol; 2023; 15():17588359231157632. PubMed ID: 36895851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New insights in the paradigm of upregulation of tumoral PSMA expression by androgen receptor blockade: Enzalutamide induces PSMA upregulation in castration-resistant prostate cancer even in patients having previously progressed on enzalutamide.
    Rosar F; Dewes S; Ries M; Schaefer A; Khreish F; Maus S; Bohnenberger H; Linxweiler J; Bartholomä M; Ohlmann C; Ezziddin S
    Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):687-694. PubMed ID: 31901103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.